In this episode of the Morale Monologue, I’m giving everyone information regarding Avexis Pharmaceutical, and their announcement regarding their expansion of operations to North Carolina. Illinois-based AveXis, a Novartis company, is developing AVXS-101, a proprietary gene therapy that could prove to be a transformative treatment for babies and children with SMA types 1, 2 and 3. These treatments will also benefit adults with SMA in the coming future. AveXis is anticipated to invest about $55 million into the new facility and open up about 200 new jobs, giving a boost to the state’s economy while improving its capabilities to manufacture therapies targeting rare neurological and genetic diseases, including spinal muscular atrophy (SMA).
SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.